Clinical and Experimental Medicine, Год журнала: 2023, Номер 23(8), С. 4251 - 4264
Опубликована: Ноя. 18, 2023
Язык: Английский
American Journal of Hematology, Год журнала: 2023, Номер 98(12), С. 1856 - 1868
Опубликована: Сен. 29, 2023
Abstract In this retrospective international multicenter study, we describe the clinical characteristics and outcomes of patients with chronic lymphocytic leukemia (CLL) related disorders (small lymphoma high‐count monoclonal B lymphocytosis) infected by SARS‐CoV‐2, including development post‐COVID condition. Data from 1540 CLL SARS‐CoV‐2 January 2020 to May 2022 were included in analysis assigned four phases based on cases disposition variants emergence. Post‐COVID condition was defined according WHO criteria. Patients during most recent pandemic, though carrying a higher comorbidity burden, less often hospitalized, rarely needed intensive care unit admission, or died compared initial phases. The 4‐month overall survival (OS) improved through phases, 68% 83%, p = .0015. Age, comorbidity, CLL‐directed treatment, but not vaccination status, emerged as risk factors for mortality. Among survivors, 6.65% had reinfection, usually milder than one, 16.5% developed latter characterized fatigue, dyspnea, lasting cough, impaired concentration. Infection severity only factor developing post‐COVID. median time resolution 4.7 months. OS different likely due improvement prophylactic therapeutic measures against well emergence variants. However, mortality remained relevant significant number conditions, warranting further investigations.
Язык: Английский
Процитировано
15
The Lancet Haematology, Год журнала: 2025, Номер 12(4), С. e238 - e239
Опубликована: Апрель 1, 2025
Язык: Английский
Процитировано
0
eJHaem, Год журнала: 2025, Номер 6(1)
Опубликована: Янв. 6, 2025
Abstract Objectives Patients with chronic lymphocytic leukaemia (CLL) have an increased risk of severe coronavirus disease 2019 (COVID‐19) as well impaired responses to COVID‐19 vaccination, which may be overcome by repeated booster vaccinations. Our objective was explore the uptake vaccine in this population since records are scarce. Methods In nationwide cohort study, we used multiple population‐based health and sociodemographic registries study individuals CLL Sweden, from 27 December 2020 28 February 2023. Results A total 6304 were included. The cumulative incidence (95% confidence interval) at end period 95%, 94%, 88%, 78% 56% for first, second, third, fourth fifth doses, respectively. significantly higher compared age‐standardized uptake. However, there large disparities, especially across different age groups, birth regions, income quartiles. These differences pronounced intersectional analyses, where born abroad lowest quartile had a only 49% 24% Conclusions Even though generally high CLL, it seems declining dose three onwards, significant disparities
Язык: Английский
Процитировано
0
Annals of Hematology, Год журнала: 2024, Номер unknown
Опубликована: Июль 15, 2024
Язык: Английский
Процитировано
1
Frontiers in Oncology, Год журнала: 2024, Номер 14
Опубликована: Сен. 10, 2024
Ibrutinib, a highly effective inhibitor of the Bruton tyrosine kinase, has significantly transformed therapeutic approach in chronic lymphocytic leukemia (CLL). Despite these advancements, disease continues to be characterized by immune dysfunction and increased susceptibility infections, with mortality rates from infections showing no significant improvement over past few decades. Therefore, timely prevention, recognition, treatment remains an important aspect standard management patient CLL. A panel hematologists expertise CLL met discuss existing literature clinical insights for infectious undergoing ibrutinib treatment. not being fully comprehensive review on topic, this work provides set practical recommendations that can serve as guide healthcare professionals who manage patients their daily practice.
Язык: Английский
Процитировано
0
Frontiers in Oncology, Год журнала: 2024, Номер 14
Опубликована: Фев. 19, 2024
Citation: Visentin A and Gentile M (2024) Editorial: Covid-19 therapies in patients with hematologic malignancies. Front. Oncol. 14:1382268. doi: 10.3389/fonc.2024.1382268
Язык: Английский
Процитировано
0
Опубликована: Янв. 1, 2024
Patients with chronic lymphocytic leukaemia (CLL) have an increased risk of severe COVID-19 due to disease- and treatment-related immune defects. Furthermore, individuals CLL impaired responses vaccination, but repeated booster vaccinations been shown increase both seroconversion rates antibody levels. However, studies addressing vaccination coverage in this frail population is lacking. In nationwide cohort study, we used multiple population-based health sociodemographic registries study vaccine uptake Sweden. The period ranged from 27 December 2020 until 28 February 2023. A total 6,304 were included. cumulative incidence (95% confidence interval) at the end was 95% (94%-96%) for first dose, 94% (94%-95%) second 88% (87%-89%) third 78% (76%-79%) fourth 56% (55%-58%) fifth dose. significantly higher compared age-standardized uptake. there large disparities, especially doses, across different age groups, birth regions, income quartiles. These differences pronounced intersectional analyses, combining these parameters. Individuals born abroad lowest quartile had a only 49% 24% respectively. Since tend need doses mount sustain findings call implementation targeted campaigns subgroups vulnerable patients.
Язык: Английский
Процитировано
0
Blood Advances, Год журнала: 2024, Номер 9(1), С. 162 - 165
Опубликована: Окт. 25, 2024
Язык: Английский
Процитировано
0
Clinical and Experimental Medicine, Год журнала: 2023, Номер 23(8), С. 4251 - 4264
Опубликована: Ноя. 18, 2023
Язык: Английский
Процитировано
1